S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Thomas K. Equels, the CEO and President of AIM ImmunoTech (OTC:AIMID) Inc. (NYSE:AIM), recently acquired additional shares of the company. The transaction comes as the stock has shown mixed performance, with a 71% gain over the past year despite falling 38% in the last six months, according to InvestingPro data. According to a recent filing, Equels purchased 103 shares of AIM ImmunoTech common stock at a price of $8.70 per share, totaling $896. Following this transaction, Equels now holds a total of 38,675 shares in the company. This move reflects Equels’ continued investment in the company he leads, as he maintains both directorial and executive roles. The company, currently valued at $77 million, maintains a strong financial position with more cash than debt and liquid assets exceeding short-term obligations. InvestingPro subscribers can access 8 additional key insights about AIM’s financial health and valuation metrics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.